Alivus Life Sciences to acquire 9.21% of Torrent Urja 19 Private Limited
Alivus Life Sciences (ALIVUS) said it has agreed a deal to acquire 9.21% of Torrent Urja 19 Private Limited. The company is valued at about ₹16,861 crore.
What happened
In a filing with the BSE on 7 October 2026 at 05:16 PM, Alivus Life Sciences (ALIVUS) said that it has agreed a deal to acquire 9.21% of Torrent Urja 19 Private Limited.
Company snapshot
Alivus Life Sciences is a small-cap company in the Healthcare sector, with a market value of about ₹16,861 crore.
The stock last traded at ₹1,373.7, against a 52-week range of ₹819–₹1,493.8 (8.0% below the high).
Before this filing the shares had moved −3.2% over the month and +20.0% over three months. Average daily turnover over the last 20 sessions was about ₹16.81 crore.
Promoters held 74.87% at the end of Q1 FY27. Foreign institutions owned 5.54% and domestic institutions 7.18%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 602 | 121.5 | 9.91 |
| Q2 FY26 | 588 | 130 | 10.6 |
| Q3 FY26 | 673 | 150.3 | 12.25 |
| Q4 FY26 | 689 | 162.7 | 13.23 |
| Q1 FY27 | 640 | 160.1 | 13.04 |
What history shows
BCEIE's records show 1 previous m&a filing from the company since May 2026.
Across 131 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +1.1% over five days; 61% of them rose the next day.
Market-wide, 1,975 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.